TCD601 for Kidney

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Kidney
TCD601 - Biological
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test how well a new drug works in combination with bone marrow cells from a donor to help prevent organ rejection in people who have recently received a kidney transplant.

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 24 months

24 months
The incidence of biopsy proven acute rejection, death and graft loss
The incidence of de novo donor-specific antibody
The optimal regimen for renal allograft tolerance while minimizing chimeric transition syndrome

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

Arm 1
1 of 3
Arm 2
1 of 3
Arm 3
1 of 3

Experimental Treatment

18 Total Participants · 3 Treatment Groups

Primary Treatment: TCD601 · No Placebo Group · Phase 2

Arm 1
Biological
Experimental Group · 1 Intervention: TCD601 · Intervention Types: Biological
Arm 2
Biological
Experimental Group · 1 Intervention: TCD601 · Intervention Types: Biological
Arm 3
Biological
Experimental Group · 1 Intervention: TCD601 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

ITB-Med LLCLead Sponsor
2 Previous Clinical Trials
36 Total Patients Enrolled
Nick Hryciw, MAStudy DirectorITB-MED
1 Previous Clinical Trials
24 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: November 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.